-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Fulcrum Therapeutics, Raises Price Target to $9

Benzinga·05/29/2025 16:54:46
Listen to the news
Piper Sandler analyst Edward Tenthoff maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price target from $6 to $9.